Aurobindo Pharma Ltd.

AUROPHARMA

₹1237.1

-0.19% (-2.4)

Market Cap

₹71,985 Cr.

P/E

20.10

About

Aurobindo Pharma Limited is a leading Active Pharmaceutical Ingredients (API) manufacturing company with a focus on cost leadership and flexibility. Its API business drives profitability and growth in… Read more

Aurobindo Pharma Limited is a leading Active Pharmaceutical Ingredients (API) manufacturing co… Read more

Low

959

52W Range

High

1592

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

7 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Pledge

Promoters have pledged a significant portion of their holding
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
Share price

Share price has increased over last 10 years due to earnings
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
ROE

Roe has decreased vs 10 year trend
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

6.80 %

(as of Mar 21)

Source/Historic

Rx Market Share - USA

Revenue mix

Product Wise Break-Up

Product Wise Break-Up - API

Location Wise Break-Up

Dosage Form Break-Up - USA Formulation

Asset Break-Up

Operational Metrics

US DMF Filings (.)
Source
Europe DMF Filings (.)
Source
Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Suppliers

Laurus Labs Ltd.
Neuland Laboratories Ltd.
Atul Ltd.
Navin Fluorine International Ltd.
Kirloskar Pneumatic Company Ltd.
Balaji Amines Ltd.
Shaily Engineering Plastics Ltd.
HLE Glascoat Ltd.
Chemcon Speciality Chemicals Ltd.

Showing 5 of 9

FAQs on Aurobindo Pharma Ltd. Business

What does Aurobindo Pharma do?

Aurobindo Pharma is a leading API manufacturing company with a strong presence in various therapeutic domains. Its advanced R&D infrastructure supports the development and delivery of new products, ensuring profitability and growth.

Who are the competitors of Aurobindo Pharma?

Aurobindo Pharma major competitors are Alkem Laboratories, Abbott India, Lupin, Zydus Lifesciences, Dr. Reddy's Lab, Mankind Pharma, Glenmark Pharma.
Market Cap of Aurobindo Pharma is ₹72,891 Crs.
While the median market cap of its peers are ₹94,276 Crs.

Is Aurobindo Pharma financially stable compared to its competitors?

Aurobindo Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Aurobindo Pharma is 5.33 and is ranked 8 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Company Filing

	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Investor Presentation	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by OpenAI	Dec			Mar Jun	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec